Holen Sie sich die Stockscreener-App
2.70
2.53%
-0.07
Handel nachbörslich:
2.82
0.12
+4.44%
Schlusskurs vom Vortag:
$2.77
Offen:
$2.67
24-Stunden-Volumen:
311.74K
Relative Volume:
0.73
Marktkapitalisierung:
$52.61M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.94M
KGV:
-0.7031
EPS:
-3.84
Netto-Cashflow:
$-22.97M
1W Leistung:
+1.12%
1M Leistung:
-0.37%
6M Leistung:
+3.85%
1J Leistung:
-66.08%
1-Tages-Spanne:
$2.58
$2.9401
1-Wochen-Bereich:
$2.53
$2.95
52-Wochen-Spanne:
$1.11
$10.54
Annovis Bio Inc Stock (ANVS) Company Profile
Firmenname
Annovis Bio Inc
Sektor
Branche
Telefon
484-875-3192
Adresse
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Vergleichen Sie ANVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.70 | 54.95M | 0 | -40.94M | -22.97M | -3.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Hochstufung | Maxim Group | Hold → Buy |
| 2023-12-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results - GlobeNewswire
ANNOVIS BIO -REDH Earnings Results: $ANVS Reports Quarterly Earnings - Quiver Quantitative
Annovis Reports Q2 2025 Financial Results, Drives Enrollment for Phase 3 AD Trial - AInvest
Annovis Bio, Inc. SEC 10-Q Report - TradingView
Annovis Advances Alzheimer's Phase 3 Trial With 76 Sites, Reports Stronger Cash Position - Stock Titan
Annovis Bio Secures Full Patent Protection for New Crystal Form of Alzheimer’s Drug Buntanetap - MSN
Annovis Bio ANVS Q2 2025 Earnings Preview Upside Potential on Strategic Innovations - AInvest
How sensitive is Annovis Bio Inc. to inflationTechnical Confluence Stock Ideas - mustnews.co.kr
RSI Reset May Fuel Rebound in Annovis Bio Inc.Weekly Stock Watch With Growth Focus Expanded - beatles.ru
Annovis Bio completes full patent transfer to crystal buntanetap - TipRanks
Annovis Completes Full Patent Transfer to Crystal Buntanetap - Santé log
Annovis secures IP protection for both forms of buntanetap By Investing.com - Investing.com Australia
Annovis secures IP protection for both forms of buntanetap - Investing.com India
Annovis Locks Down Patent Protection Until 2046 for Promising Alzheimer's and Parkinson's Treatment - Stock Titan
Bullish Candlestick Pattern Forms in Annovis Bio Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
How many analysts rate Annovis Bio Inc. as a “Buy”Achieve rapid financial growth with expert picks - Jammu Links News
What makes Annovis Bio Inc. stock price move sharplyBuild a strong portfolio for long-term success - Jammu Links News
What are analysts’ price targets for Annovis Bio Inc. in the next 12 monthsAccelerated earnings growth - Jammu Links News
What are Annovis Bio Inc. company’s key revenue driversFree Trend-Following Techniques - Jammu Links News
How does Annovis Bio Inc. compare to its industry peersMassive portfolio appreciation - Jammu Links News
Is Annovis Bio Inc. stock overvalued or undervaluedRapid growth trajectories - Jammu Links News
How volatile is Annovis Bio Inc. stock compared to the marketGrow your wealth steadily and securely - Jammu Links News
Why is Annovis Bio Inc. stock attracting strong analyst attentionUnlock powerful portfolio optimization tools - Jammu Links News
Recovery Setup Building in Annovis Bio Inc. Experts SayStrong Buy With Technical Confidence Supported - metal.it
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection - 富途牛牛
What catalysts could drive Annovis Bio Inc. stock higher in 2025Swing Trade Insights With Proven Results - Jammu Links News
Will Annovis Bio Inc. Stock Benefit from AI and Green Energy TrendsTrade Scanner With Buy Zone Alerts Flagged - metal.it
Annovis Bio Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingTrade Insight With Community Collaboration Supported - metal.it
Will Annovis Bio Inc. stock split in the near futureChart-Based Trade Entries Gain Analyst Support - metal.it
What is Annovis Bio Inc. company’s growth strategyMaximize your returns with expert insights - Jammu Links News
Should I hold or sell Annovis Bio Inc. stock in 2025Accelerated capital growth - Jammu Links News
Is Annovis Bio Inc. a growth stock or a value stockConsistently exceptional gains - Jammu Links News
Why Annovis Bio Inc. stock attracts strong analyst attentionBreakout Momentum Stocks - metal.it
Annovis Bio Inc. Stock Analysis and ForecastFree Predictions - PrintWeekIndia
Is Annovis Bio Inc. a good long term investmentFree Real-Time Stock Data - PrintWeekIndia
What analysts say about Annovis Bio Inc. stockExceptional growth trajectory - PrintWeekIndia
Annovis Bio Inc.’s Promising Alzheimer’s Drug Trial: Key Updates for Investors - TipRanks
Finanzdaten der Annovis Bio Inc-Aktie (ANVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):